RxDoctor Payments Data

Lindsey Vollono, PA

Medical · Charleston, SCNPI 1477836286

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,479 of the $10,026 with a category attached, or 74.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.3%. Among medical clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,026in general payments, 2019–2025

Across 369 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • BTG International Inc.$1K
  • Merck$513
  • AstraZeneca$415
  • Johnson & Johnson$414
  • E.r. Squibb & Sons, L.L.C.$373
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$1,00010%
  • Food & beverage$7,47975%
  • Education$1001%
  • Other$1,44614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis38$1,934
BTG International Inc.1$1,000
Merck22$513
AstraZeneca(2 entities)21$415
Johnson & Johnson(2 entities)18$414
E.r. Squibb & Sons, L.L.C.22$373
Gilead(2 entities)9$333
Sanofi11$283
Jazz Pharmaceuticals Inc.13$274
Lilly USA, LLC11$263
Pfizer15$249
Regeneron Healthcare Solutions, Inc.12$223
Takeda Pharmaceuticals U.S.A., Inc.9$221
Incyte Corporation9$194
Amgen8$186
Genentech USA, Inc.9$175
Rigel Pharmaceuticals, Inc.7$164
Seagen Inc.9$163
Daiichi Sankyo Inc.6$157
GSK7$145
Taiho Oncology, Inc.7$142
Array Biopharma Inc9$138
Karyopharm Therapeutics Inc.6$138
Puma Biotechnology, Inc.6$120
Servier Pharmaceuticals LLC6$109
Ipsen Biopharmaceuticals, Inc5$108
AbbVie5$105
Sanofi-aventis U.S. LLC1$100
Bayer6$97
Eisai Inc.4$96
Acrotech Biopharma Inc.4$96
Astellas Pharma US Inc4$86
Bristol Myers Squibb4$79
Pharmacyclics LLC, An Abbvie Company4$62
Beone Medicines USA, Inc.2$56
ADC Therapeutics America, Inc.3$54
Beigene USA, Inc.3$52
Boehringer Ingelheim2$50
Alnylam Pharmaceuticals Inc.2$50
Pharmaessentia USA Corporation2$48
G1 Therapeutics, Inc.2$44
Azurity Pharmaceuticals, Inc.2$44
AVEO Pharmaceuticals, Inc.2$43
Sumitomo Pharma America, Inc.1$29
Adaptive Biotechnologies Corporation1$28
CTI Biopharma Corp.2$27
Geron Corporation1$27
Novocure Inc.1$25
Heron Therapeutics, Inc.1$25
Mirati Therapeutics, Inc.1$24
Forte Bio-pharma LLC1$23
Genmab U.S., Inc.1$23
Medtronic1$21
Morphosys, US Inc.1$20
Deciphera Pharmaceuticals Inc.1$20
Stemline Therapeutics Inc.1$20
Cycle Pharmaceuticals Inc1$20
Syndax Pharmaceuticals, Inc.1$19
Tolmar, Inc.1$19
Tersera Therapeutics LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,026 in reported general payments places this provider in the 90th percentile of 384 medical providers in South Carolina.

See all medical providers in South Carolina

Medicare billing

Part B allowed, 2024
$70,299
Medicare patients
312
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DopteletAvatrombopag Maleate13$143,271
EliquisApixaban131$99,826
OrgovyxRelugolix20$50,734
Abiraterone Acetate29$21,293
XareltoRivaroxaban12$14,500
Anastrozole58$2,712
Mirtazapine26$850
Oxycodone Hcl29$800
Acyclovir29$740
Letrozole26$733
Tamoxifen Citrate34$622
Ondansetron Hcl26$429
Dexamethasone21$419
Escitalopram Oxalate16$260
Promethazine Hcl20$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$249$99,826131 claims
Sumitomo Pharma America, Inc.Orgovyx$29$50,73420 claims
Johnson & JohnsonXarelto$414$14,50012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 384 medical providers in South Carolina.

Other medical in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →